EMA approves 39 drugs in H1, down from 44 last year

The European Medicines Agency approved 39 new drugs in the first half of the year, PharmaTimes reports. This marks an 11% decline from the 44 it had approved in the first half of 2013 but 6 more than it had in the first half of 2012. The publication points out that a number of the drugs provide treatment for conditions for which there were none before, like GlaxoSmithKline's ($GSK) cancer drug Mekinist and Roche's ($RHHBY) cancer drug Gazyvaro, among others. Story

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.